Guojin Securities released a research report on April 23 stating that it gave Tebao Biotech (688278.SH) a purchase rating. The main reasons for the rating include: 1) clinical evidence of hepatitis B cure continues to accumulate, and Pegobin continues to be rapidly released; 2) Key R&D projects are being accelerated, and the product pipeline is expected to continue to be rich. (Mainichi Keizai Shimbun)
国金证券4月23日发布研报称，给予特宝生物（688278.SH）买入评级。评级理由主要包括：1）乙肝治愈临床证据不断积累，派格宾持续快速放量；2）重点研发项目加速推进，产品管线有望持续丰富。（每日经济新闻）
Guojin Securities released a research report on April 23 stating that it gave Tebao Biotech (688278.SH) a purchase rating. The main reasons for the rating include: 1) clinical evidence of hepatitis B cure continues to accumulate, and Pegobin continues to
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.